You just read:

A Pancreatic and Colorectal Cancer Trial Initiated to Address the Needs of Patients With Immune Checkpoint Inhibitor (ICI)-resistant Disease by Combining Debiopharm's Debio 1143 IAP Antagonist With Keytruda®

News provided by

Debiopharm International SA

09 Oct, 2019, 07:00 BST